Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 5/20 | 0.45 |
| ▸ | MAOA | P21397 | 8/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SDHA | P31040 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427247 | 1.00 | CALML3 (0.45) | CALML3MAOAGRM2MAOBLMNA | |
| SCHEMBL3200191 | 0.87 | CALML3 (0.45) | CALML3MAOAGRM2MAOBLMNA | |
| SCHEMBL440920 | 0.87 | CALML3 (0.45) | CALML3MAOAGRM2MAOBLMNA | |
| SCHEMBL542136 | 0.87 | CALML3 (0.47) | CALML3MAOAGRM2MAOBLMNA | |
| SCHEMBL3328227 | 0.86 | CALML3 (0.44) | CALML3MAOAGRM2MAOBLMNA | |
| SCHEMBL3327125 | 0.84 | GRM2 (0.48) | GRM2 | |
| SCHEMBL4564670 | 0.84 | GRM2 (0.48) | GRM2 | |
| SCHEMBL17811402 | 0.82 | CALML3 (0.47) | CALML3MAOAGRM2MAOBLMNA | |
| SCHEMBL3194729 | 0.81 | CALML3 (0.41) | CALML3MAOAGRM2MAOBLMNA | |
| SCHEMBL3198635 | 0.81 | CALML3 (0.41) | CALML3MAOAGRM2MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646629-B1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK SHARP & DOHME (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-7582659-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7462633-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7396847-B2 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| US-7396847-B2 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | MERCK & CO., INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1654259-A1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1646629-A2 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1427711-B1 | OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK SHARP & DOHME CORP. | 2005-02-17 | — | — | US | disclosed |
| WO-2005005420-A1 | CYCLOPROPYL GROUP SUBSTITUTED OYAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005005398-A2 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| EP-1427711-A1 | OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003022824-A1 | OXAZOLIDINONE AND/OR ISOXAZOLINE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | CALML3 3370/4885MAOA 2977/4885GRM2 3338/4885 |
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | CYP8B1, HRH2, CYP2W1 | CALML3 4624/4885MAOA 482/4885GRM2 2199/4885 |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | CYP8B1, CYP2W1, HRH2 | CALML3 4637/4885MAOA 800/4885GRM2 2354/4885 |
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | IL17A, COASY, OXA1L | CALML3 3443/4885MAOA 2435/4885GRM2 3644/4885 |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | CALML3 3370/4885MAOA 2977/4885GRM2 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.